课题基金 / 基金详情

GLIAL B-AMYLOID PEPTIDE RECEPTORS IN ALZHEIMER'S DISEASE

GLIAL B-AMYLOID PEPTIDE RECEPTORS IN ALZHEIMER'S DISEASE
阿尔茨海默病中的胶质 B 淀粉样肽受体
批准号:
3488131
负责人:
KURT R. BRUNDEN
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-01-15 至 1993-09-14

项目摘要

项目成果

KURT R. BRUNDEN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(改编自申请者的摘要):病理性的 阿尔茨海默病的特征是出现老年斑 含有β-淀粉样多肽(BAP)。这些斑块似乎是 与普通淀粉样斑块不同的是,它们含有小胶质细胞和 斑块浓缩核心内及周围的星形胶质细胞。这 观察结果促使人们假设,小胶质细胞和星形胶质细胞可能 在阿尔茨海默病的斑块形成和病理中起关键作用 疾病。布伦登博士推测,这些胶质细胞有表面 BAP的受体,并提出了一种生化事件理论, 可能会导致阿尔茨海默病的病理。这个理论有一定的道理 比如:胶质细胞有P物质受体。小胶质细胞是中枢神经系统 相当于巨噬细胞,巨噬细胞有一种受体,称为 与P物质和BAP结合的丝氨酸-酶复合体(SEC)。因此, PI假设神经胶质细胞具有SEC受体或特异性受体 巴普。他进一步假设BAP结合在神经胶质细胞表面 受体诱导白细胞介素1(IL-1)的释放。升高的IL-1 可导致淀粉样前体蛋白(APP)增加,其中BAP是 一种蛋白水解物BYE,从而通过 BAP进一步上升。据推测,IL-1会增加 花生四烯酸和前列腺素E2(PGE2),从而诱导谷氨酸 星形胶质细胞摄取酸性物质。这可能会导致谷氨酸过量。 会产生兴奋毒性并导致神经细胞死亡的水平,因此 促进阿尔茨海默氏症。 作为初步数据,首席调查员已经聘请了一名 人脑胶质母细胞瘤细胞系U373-MG和新生大鼠原代培养 如果这些细胞含有受体,则间接地终止星形胶质细胞 识别BAP和P物质(可能的SEC受体)。布伦登博士 发现~(125)I-P物质与这些神经胶质细胞特异结合。 使用竞争结合分析,他还证明了这种结合是 被氨基酸残基BAP(1-40)和BAP(25-35)抑制,但不 BAP(1-28)。这些结果表明,细胞表面可能存在一种SEC受体 神经胶质细胞。 提出的目标是:1]检测125I-BAP(1-40)与小胶质细胞的结合 以及培养的星形胶质细胞是否存在BAP受体。萨查德 分析和竞争研究将被用来证明 BAP结合的饱和性、亲和力和特异性。2]以确定 如果BAP与星形胶质细胞和小胶质细胞培养中的受体结合增加 IL-1分泌。这将使用胸腺细胞的变种进行评估。 共刺激生物测定法,用于测量特定T细胞的增殖 刀豆蛋白A刺激后出现的辅助细胞系,仅当 存在外源性IL-1。3]以确定BAP结合是否诱导 从小胶质细胞、星形胶质细胞或混合胶质细胞培养中释放PGE2。这个 PGE2将使用商业RIA试剂盒进行测量。 如果所提出的细胞事件“级联”的演示是 如果成功,第二阶段的应用将使用各种抑制剂和 拮抗剂(如到BAP、IL-1、PGE2的合成)来研究可能的 阻止或减缓阿尔茨海默病进展的机制。
英文摘要
DESCRIPTION (Adapted from applicant's abstract): One of the pathological hallmarks of Alzheimer's Disease is the presence of senile plaques containing beta-amyloid peptide (BAP). These plaques seem to be different from ordinary amyloid plaques in that they have microglia and astrocytes within and around the condensed core of the plaque. This observation prompted the hypothesis that microglia and astrocytes may play a crucial role in plaque formation and the pathology of Alzheimer's disease. Dr. Brunden has postulated that these glia have surface receptors for BAP and has put forth a theory of biochemical events which may lead to Alzheimer's Disease pathology. The theory goes something like this: Glia have substance P receptors. Microglia are the CNS equivalent of macrophages, and macrophages have a receptor called the serpin-enzyme complex (SEC) which binds both substance P and BAP. Thus, the PI postulates that glia have a SEC receptor or specific receptor for BAP. He further postulates that the BAP binding on glial surface receptors induces release of interleukin 1 (IL-1). The increased IL-1 could cause increased amyloid precursor protein (APP), of which BAP is a proteolytic bye product, and thereby advanced Alzheimer's Disease by increasing BAP even further. It is also postulated that IL-1 increases arachidonic acid and prostaglandin E2 (PGE2), thereby inducing glutamic acid uptake by astrocytes. This could result in excessive glutamate levels that would be excitotoxic and lead to neural cell death, thus promoting Alzheimer's Disease. As a preliminary data, the principal investigator has employed both a human glioblastoma cell line, U373 MG, and neonatal rat primary astrocetermine indirectly if these cells contains receptors that recognize both BAP and substance P (putative SEC receptors). Dr. Brunden found that 125I-substance P binds specifically to these glial cells. Using competitive binding assays he also showed that this binding was inhibited by the amino acid residues BAP (1-40) and BAP (25-35), but not by BAP (1-28). These results suggests that a SEC receptor may exist on glial cells. The proposed aims are: 1] to examine 125I-BAP (1-40) binding to microglia and astrocytes in culture for the presence of BAP receptors. Satchard analyses and competition studies will be used to demonstrate saturability, affinity and specificity of BAP binding. 2] to determine if BAP binding to receptors in astrocyte and microglia cultures increases IL-1 secretion. This will be assessed using a variation of the thymocyte costimulation bioassay which measures the proliferation of a certain T helper cell line that occurs after concanavalin A stimulation, only if exogenous IL-1 is present. 3] to determine if BAP binding induces the release of PGE2 from microglia, astrocytes or mixed glial cultures. The PGE2 will be measured using a commercial RIA kit. If the demonstration of the proposed "cascade" of cellular events is successful, the Phase II application would employ various inhibitors and antagonists (eg. to BAP, IL-1, PGE2 synthesis) to investigate possible mechanisms of halting of slowing the progress of Alzheimer's Disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies
  • 批准号:
    10364719
  • 项目类别:
  • 资助金额:
    $74.61万
  • 财政年份:
    2019
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies
  • 批准号:
    10398425
  • 项目类别:
  • 资助金额:
    $15.99万
  • 财政年份:
    2019
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies
  • 批准号:
    10553899
  • 项目类别:
  • 资助金额:
    $31.15万
  • 财政年份:
    2019
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment
  • 批准号:
    8478876
  • 项目类别:
  • 资助金额:
    $47.86万
  • 财政年份:
    2013
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
海外基金